Avenue Therapeutics, Inc. Gains 105.9%
Thu, Sep 22, 2022 at 07:26 PM
Avenue Therapeutics, Inc. (ATXI:NASDAQ) rocketted at $0.44, representing a gain of 105.9%. On Thu, Sep 22, 2022, ATXI:NASDAQ touched a New 2-Week High of $0.44. The stock got featured on our News Catalysts scanner on Thu, Sep 22, 2022 at 04:45 PM in the 'BIOTECH' category. From Thu, Sep 08, 2022, the stock recorded 40.00% Up Days and 36.36% Green Days
The stock spiked on Wed, Sep 14, 2022 at $0.59 with a volume of 65M+.
About Avenue Therapeutics, Inc. (ATXI:NASDAQ)
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of an intravenous, or IV, formulation of tramadol HCl, or IV Tramadol, for the management of moderate to moderately severe postoperative pain.
Top 10 Gainers:
- Spero Therapeutics, Inc. (SPRO:NASDAQ), 167.74%
- Avenue Therapeutics, Inc. (ATXI:NASDAQ), 105.9%
- Panbela Therapeutics Inc. (PBLA:NASDAQ), 46.39%
- American Virtual Cloud Technologies, Inc. (AVCT:NASDAQ), 44.69%
- ShiftPixy, Inc. (PIXY:NASDAQ), 38.95%
- Cassava Sciences, Inc. (SAVA:NASDAQ), 35.65%
- Cano Health Inc. Class A (CANO:NYSE), 32.17%
- iSpecimen Inc. (ISPC:NASDAQ), 26.49%
- Heliogen Inc. (HLGN:NYSE), 23.56%
- Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ), 23.48%